bpc-157 and thymosin beta 4 TB 500 vs BPC 157: Comprehensive comparison of healing peptides TB4 and TB-500 Peptide Therapy

This study is the first preclinical pharmacokinetic study of BPC157, and the results are of considerable importance, as they demonstrate not only the pharmacokinetic parameters of BPC157 but also show the implications for its systemic application as a novel drug for various injuries

Follow post-care instructions

Product Specifications Detailed Mechanism of Action AOD-9604 is designed to replicate the lipolytic C-terminal tail of growth hormone while excluding the sequence regions responsible for IGF-1 elevation and insulin antagonism

There is a low risk of serious side effects when administered by a qualified professional

Then a lab analyzed BS-2025 and found it was an inert placebo and you know what the BS stand for

Click image for larger view